title: [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
abstract: Since the Korean College of Helicobacter and Upper Gastrointestinal Research has first developed the guideline for the diagnosis and treatment of Helicobacter pylori infection in 1998, the revised guideline was proposed in 2009 by the same group. Although the revised guideline was made by comprehensive review of previous articles and consensus of authoritative expert opinions, the evidence-based developmental process was not applied in the revision of the guideline. This new guideline has been revised especially in terms of changes in the indication and treatment of H. pylori infection in Korea, and developed by the adaptation process as evidence-based method; 6 guidelines were retrieved by systematic review and the Appraisal of Guidelines for Research and Evaluation (AGREE) II process, 21 statements were made with grading system and revised by modified Delphi method. After revision, 11 statements for the indication of test and treatment, 4 statements for the diagnosis and 4 statements for the treatment have been developed, respectively. The revised guideline has been reviewed by external experts before the official endorsement, and will be disseminated for usual clinical practice in Korea. Also, the scheduled update and revision of the guideline will be made periodically.
authors: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Sang Gyun
authors: SG
authors: Kim
authors: Hye Kyung
authors: HK
authors: Jung
authors: Hang Lak
authors: HL
authors: Lee
authors: Jae Young
authors: JY
authors: Jang
authors: Hyuk
authors: H
authors: Lee
authors: Chan Gyoo
authors: CG
authors: Kim
authors: Woon Geon
authors: WG
authors: Shin
authors: Ein Soon
authors: ES
authors: Shin
authors: Yong Chan
authors: YC
authors: Lee
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D001944:Breath Tests; D017291:Clarithromycin / Q000627:therapeutic use; D005764:Gastroesophageal Reflux / Q000209:etiology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications; D008679:Metaplasia / Q000150:complications; D008795:Metronidazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D056910:Republic of Korea; D013274:Stomach Neoplasms / Q000150:complications / Q000601:surgery; D013752:Tetracycline / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin; D001241:Aspirin; D001729:Bismuth